Dihydropyranone formation by ipso C-H activation in a glucal 3-carbamate-derived rhodium acyl nitrenoid.

By using (N-tosyloxy)-3-O-carbamoyl-D-glucal 10, which removes the need for a hypervalent iodine(III) oxidant, we provide evidence for rhodium nitrenoid-mediated ipso C-H activation as the origin of a C3-oxidized dihydropyranone product 3. This system may be especially susceptible to such a pathway because of the ease of forming a cation upon hydride transfer to the rhodium-complexed acyl nitrene.

Anthranilic acid replacements in a niacin receptor agonist.

Niacin is an effective drug for raising HDL cholesterol. However, niacin must be taken in large doses and significant side effects are often observed, including facial flushing, loss of glucose tolerance, and liver toxicity. An anthranilic acid was identified as an agonist of the niacin receptor. In order to improve efficacy and provide structural diversity, replacements for the anthranilic acid were investigated and several compounds with improved properties were identified.

Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.

Niacin is an effective drug for raising HDL cholesterol and reducing coronary risks, but patients show low compliance with treatment due to severe facial flushing upon taking the drug. A series of bicyclic pyrazole carboxylic acids were synthesized and tested for their ability to activate the niacin receptor. One analog, 23, showed improved potency and lacked flushing at doses that effectively altered the lipid profile of rats.

4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV.

A novel series of 4-arylcyclohexylalanine DPP-4 inhibitors was synthesized and tested for inhibitory activity as well as selectivity over the related proline-specific enzymes DPP-8 and DPP-9. Optimization of this series led to 28 (DPP-4 IC(50)=4.8 nM), which showed an excellent pharmacokinetic profile across several preclinical species. Evaluation of 28 in an oral glucose tolerance test demonstrated that this compound effectively reduced glucose excursion in lean mice.

Alpha-N-acetylmannosamine (ManNAc) synthesis via rhodium(II)-catalyzed oxidative cyclization of glucal 3-carbamates.

[reaction: see text] Glucal 3-carbamates 1 and 7 underwent oxidative cyclization with iodobenzene diacetate or iodosobenzene in the presence of Rh2(OAc)4, providing mannosamine 2-N,3-O-oxazolidinones. With iodosobenzene, incorporation of 4-penten-1-ol provided a readily separable anomeric mixture of n-pentenyl glycosides, with the anomers exhibiting pronounced differences in reactivity as glycosyl donors. N-acylation of the sugar oxazolidinones led to alpha-selective glycosyl donors for the elaboration of various 2-mannosamine frameworks. Alternatively, the anomeric n-pentenyl glycosides of N-Cbz 2-mannosamine oxazolidinones were converted separately to oxazolidinone-opened derivatives 28alpha and 28beta. These served as stereoconvergent glycosyl donors, and the alpha-linked products were readily advanced to a variety of N-acetylmannosamine (ManNAc) frameworks, using an intramolecular O-->N acetyl transfer as the final step.

Homoleptic cobalt and copper phenolate A2[M(OAr)4] compounds: the effect of phenoxide fluorination.

Two series of homoleptic phenolate complexes with fluorinated aryloxide ligands A2[M(OAr)4] with M=Co2+ or Cu2+, OAr-=(OC6F5)- (OArF) or [3,5-OC6H3(CF3)2]- (OAr'), A+=K (18-crown-6)+, Tl+, Ph4P+, Et3HN+, or Me4N+ have been synthesized. Two related complexes with nonfluorinated phenoxide ligands have been synthesized and studied in comparison to the fluorinated aryloxides demonstrating the dramatic structural changes effected by modification of OPh to OAr(F). The compounds [K(18-crown-6)]2[Cu(OArF)4], 1a; [K(18-crown-6)]2[Cu(OAr')4], 1b; [Tl2Cu(OArF)4], 2a; [Tl2Cu(OAr')4], 2b; (Ph4P)2[Cu(OArF)4], 3; (nBu4N)2[Cu(OArF)4], 4; (HEt3N)2[Cu(OArF)4], 5; [K(18-crown-6)]2[Cu2(mu2-OC6H5)2(OC6H5)4], 6; [K(18-crown-6)]2[Co(OArF)4], 7a; [(18-crown-6)]2[Co(OAr')4], 7b; [Tl2Co(OArF)4], 8a; [Tl2Co(OAr')4], 8b; (Me4N)2[Co(OArF)4], 9; [Cp2Co]2[Co(OAr')4], 10; and [(18-crown-6)])[Co2(mu2-OC6H5)2(OC6H5)4], 11, have been characterized with UV-vis and multinuclear NMR spectroscopy and solution magnetic moment studies. Cyclic voltammetry was used to study 1a, 1b, 7a, and 7b. X-ray crystallography was used to characterize 1b, 3, 4, 5, 6, 7a, 7b, 10, and 11. The related [MX4]2- compound (Ph4P)2[Co(OArF)2Cl2], 12, has also been synthesized and characterized spectroscopically, as well as with conductivity and single-crystal X-ray diffraction. Use of fluorinated aryloxides permits synthesis and isolation of the mononuclear, homoleptic phenolate anions in good yield without oligomerized side products. The reaction conditions that result in homoleptic 1a and 7a with OArF upon changing the ligand to OPh result in mu2-OPh bridging phenoxides and the dimeric complexes 6 and 11. The [M(OArF)4]2- and [M(OAr')4]2- anions in 1a, 1b, 3, 4, 5, 7a, 7b, 9, and 10 demonstrate that stable, isolable homoleptic phenolate anions do not need to be coordinatively or sterically saturated and can be achieved by increasing the electronegativity of the ligand.